Clinical trialNCT06444815RecruitingPhase 1Interventional

A Study of VET3-TGI in Patients With Solid Tumors

SponsorKaliVir ImmunotherapeuticsEnrollment60Cervical CancerCutaneous Squamous Cell Carcinoma (CSCC)Head and Neck Squamous Cell CarcinomaKidney CancerMelanoma Stage IVMerkel Cell Carcinoma of Skin+7 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).

clinicaltrials.gov ↗

Investigators

No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Usc/norris Comprehensive Cancer Center
Los Angeles, California, United States
Jacob Thomas, MD
Recruiting
Uc Irvine Health
Orange, California, United States
Edward Uchio, MD
Recruiting
University of Miami
Miami, Florida, United States
Jaime Merchan, MD
Recruiting
Community Health Network
Indianapolis, Indiana, United States
Bert O'Neil, MD
Recruiting
Upmc- Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
Yana Najjar, MD
Recruiting
Mary Crowley Cancer Research
Dallas, Texas, United States
Minal Barve, MD
Recruiting
University of Texas Md Anderson Cancer Center
Houston, Texas, United States
Siqing Fu, MD, PhD
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Atezolizumab →VET3-TGI

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 16 Sept 2024
Primary completion: 30 Sept 2027
Completion: 31 Dec 2027
Last update posted: 7 Apr 2026
Registered enrollment: 60
Registry id: NCT06444815

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.